Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

Kristen Ambrose, Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotechnology company with strong financial health according ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Since its launch in 2005 the Triumph Sprint ST 1050 has been a hit, taking over from the Honda VFR800 at the top of the Sports Touring (ST - see?) tree. It’s fast, comfy, practical, reliable ...

Video by Allie Schallert, [email protected] In today’s 10 a.m. “Ten Hochman” sports video — brought to you by Roger Dean Chevrolet Stadium, home of St. Louis Cardinals spring ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...